Table 1.
Overview of longitudinal cohort data from Papua New Guinea and Thailand
| Papua New Guinea (n = 504) | Thailand (n = 999) | ||
|---|---|---|---|
| Placebo arm (n = 257) | Primaquine arm (n = 247) | ||
| Gender (male) | 49.8% (128) | 48.6% (120) | 46.2% (462) |
| Age (years) | 7.5 (4.9, 10.4) | 7.6 (4.8, 10.4) | 23 (1, 82) |
| Bednet usage | 93.4% (240) | 93.1% (230) | 88.8% (888) |
| Duration of follow-up (days) | 224 (56, 231) | 224 (42, 229) | 369 (360, 378) |
| Proportion of data missing | 12.3% | 10.1% | 8.3% |
| Any P. vivax infection by qPCR | 69.6% (179) | 27.9% (69) | 11.9% (119) |
| Any P. vivax infection by LM | 54.5% (140) | 21.9% (54) | – |
| Number of P. vivax genotypes | 2.2 (0, 12) | 0.7 (0, 7) | 0.3 (0, 11) |
| Any P. falciparum infection by qPCR | 37.0% (95) | 34.0% (84) | 2.4% (24) |
| Any P. falciparum infection by LM | 23.7% (61) | 27.9% (69) | – |
| Number of P. falciparum genotypes | 0.6 (0, 9) | 0.5 (0, 6) | 0.03 (0, 6) |
| Any fever | 53.7% (138) | 62.3% (154) | 24.7% (247) |
| Any fever with qPCR+ P. vivax | 10.1% (26) | 4.0% (10) | 2.1% (21) |
| Any fever with qPCR+ P. falciparum | 9.7% (25) | 16.6% (41) | 0.3% (3) |
The data from PNG is for the period after the initial drug regimen. Missing data is defined as the proportion of samples scheduled in the study protocols missed. Data on age, numbers of genotypes detected during follow-up, and duration of follow-up are presented as mean and ranges. Light microscopy (LM) data was not available for the Thai samples